NCT02393755View on ClinicalTrials.gov

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

May 18, 2021

Conditions
Colon AdenocarcinomaRectal AdenocarcinomaRecurrent Colon CarcinomaRecurrent Rectal CarcinomaStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
DRUG

Capecitabine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nintedanib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

91010

City of Hope Comprehensive Cancer Center, Duarte

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER

NCT02393755 - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter